DDInter915 DDInter1595
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Indacaterol {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Indacaterol {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Rilpivirine
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilpivirine
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Indacaterol {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilpivirine
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Indacaterol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Rilpivirine (Compound)
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Indacaterol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Rilpivirine
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Indacaterol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine